National and Kapodistrian University of Athens
In vitro αξιολόγηση και in vivo φαρμακοκινητική / φαρμακοδυναμική μελέτη του εκχυλίσματος από τα στίγματα του φυτού Crocus sativus L. με έμφαση στην αντιαθηρωματική δράση
Abstract
dc:descriptionBackground and aims: The aims of the present study were: 1) the production, identification and quantification of a solid aqueous saffron extract (Crocus sativus L., SFE), 2) the in vitro study of its stability and content in bioactive components, 3) the in vivo pharmacokinetic study of its main antioxidant component (crocetin after crocin hydrolysis) and 4) the investigation of its possible antiatherosclerotic properties in ApoE knockout mice (ApoE-/-) after the administration of 3 different doses (30-60-90 mg/ kg body weight) and its possible mechanism of action. Methods: The production of saffron aqueous extract was accomplished with the mixture of Crocus sativus L. stigmas with distilled water. The mixture was let in the refrigerator for 3 days till the extraction to be completed. The extract was then infiltrated and lyophilized. The lyophilized product was studied for its chemical composition with the help of semi-preparative HPLC analysis and NMR spectroscopy, and then quantified to identify its major components (crocin, safranal). The SFE was then studied for its stability concerning its major component, crocin. Intravenous and peros administration to 80 C57Bl/6J mice at a dose of 60 mg/kg body weight followed in order to assess the pharmacokinetic properties and bioavailability of the main bioactive component of SFE, crocetin (hydrolyzed form of crocin). Samples were collected at selected time points after administration (5, 15, 30, 60, 90, 120, 180 and 240 min). The quantification of crocetin in biological samples (serum and tissues) was accomplished after the optimization of an HPLC-PDA analysis method. The data obtained (Concentration vs time) for both serum and tissue samples were subjected to both compartmental and non-compartmental PK analysis to estimate the pharmacokinetic parameters and characterize crocetin’s PK profile. Finally, for the estimation of SFE’s possible antiatherosclerotic/atheroprotective effect fifty male, ApoE-/- mice, fed high-fat diet (HFD) for 12 weeks, were randomized into 5 equally numbered groups: 1) Baseline group, euthanatized, without intervention on the 12th week, 2) three saffron groups (SF1, SF2, SF3) receiving HFD and 30-,60-,90mg/kg/day of SFE, respectively, for four weeks, peros through gavage, after reconstitution in water for injection (WFI), 3) control group (COG) receiving daily HFD and the same volume of WFI (four weeks). After blood sampling and euthanasia, aortic roots were excised and analyzed for the gene expression and/or percentage of aortic stenosis, relative content of macrophages, smooth muscle cells (SMCs), connective tissue, tumor necrosis factor-α (TNF-a), monocyte chemoattractant protein-1 (MCP-1), matrix metalloproteinases-2,-3,-9 (MMP-2,-3,-9) and their inhibitor (TIMP-2) and IL-6, with the use of immunohistochemical and qRT-PCR techniques.Results: The saffron extract (SFE) that was produced was found rich in crocins and picrocrocin, whereas safranal was found in very low concentrations due to its less polar character which requires organic solvents to be solubilized. As far as its stability is concerned, SFE remains stable (crocin concentration) when kept in room temperature for a long period of time (at least 18 months), and the reconstituted solution can be re-used for the first 24 hours after reconstitution. The one-compartment model was found to describe adequately the kinetics of SFE’s main metabolite crocetin after intravenous and peros administration. After peros administration of SFE at a dose of 60 mg/kg body weight Cmax was found to be 2.77 μg/mL (%CV 2.17) and 3.84 (%CV1.6) for free and total crocetin respectively, which shows that crocin is hydrolyzed into crocetin in the intestinal lumen and then quickly absorbed (Tmax=30 min). The measurement results of the studied tissue samples show that crocetin is mainly distributed in the liver and the kidneys, which are the basic organs of its biotransformation and elimination. No measurable crocetine concentrations could be obtained from both lungs and heart samples, most probably because of its fast glucuronidation into crocetin’s metabolite. Concerning crocetin’s metabolite, the measured concentration values reveal limited distribution to the studied tissues. The results of the PK study lead to the conclusion that the administered SFE dose (60 mg/kg) was capable in achieving serum concentration levels proportional to those estimated in healthy volunteers after administration of pure crocetin (7.5 up to 22.5 mg which is equivalent to 0.11-0.32 mg/kg body weight) (1) or after administration of crocin in mice (40 nmol or 1.12 mg/kg body weight) (2). These facts suggested the use of the dosage scheme between 30 and 90 mg/kg body weight/day which correspond to 2.90-8.70 mg/kg of pure crocetin or 0.33-0.33 mg/kg of crocin for the conduction of the study for the effect of SFE in atheromatosis and inflammation generally. The study of the effect of SFE in atheromatosis, revealed that the administration of the extract did not affect body weight and total cholesterol levels (p>0.05). High SFE dose significantly ameliorated glucose and triglycerides profiles compared to other groups (p<0.05). Following a dose-dependent-manner SFE considerably decreased aortic stenosis (p<0.05). Furthermore, increasing SFE doses proportionally reduced macrophages content and increased the content of collagen, elastin, SMCs, in plaques promoting more stable plaque phenotype compared to COG (p<0.05). Those effects seemed to be associated with considerable reduction (>30%) of IL-6, TNF-a, MCP-1, MMP-2,-3,-9 (p<0.05) and MMP-2/TIMP-2 ratio. RT-qPCR analysis reassured our previous results of immunohistochemistry.Conclusions: SFE is a stable lyophilized extract rich in all trans-crocins. The PK study allowed the estimation of basic PK parameters and the bioavailability of SFE’s main bioactive component, crocetin, after peros administration and helped in the selection of the right dosage range for the evaluation of SFE’s atheroprotective and anti-atherosclerotic effect. SFE exerted dose dependent anti-atherosclerotic and plaque-stabilizing effects in Apo-E-/- mice, probably mediated by favorable modification of inflammatory mechanisms.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Christodoulou, Eirini
- Χριστοδούλου, Ειρήνη
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/43384